Advertisement
News
Subscribe to MDT Magazine News

Health care reform still divisive

December 6, 2010 8:35 am | by Mass High Tech: The Journal of New England Technology | Comments

While 40 percent of Americans want to repeal all or most of last year's health care reform bill, 31 percent want all or most of the reforms. In a Harris Interactive Poll conducted in partnership with Norwalk, Conn.-based HealthDay, the results indicate that people across the nation remain...

FDA grants study of Abiomed heart device

December 6, 2010 8:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Cardiac medical device maker Abiomed Inc. has won conditional approval from the U.S. Food and Drug Administration for a pilot study to test its Impella 2.5 device reducing heart muscle damage in patients with ST-elevation myocardial infarction (STEMI).

ArQule begins trial of cancer drug candidate

December 6, 2010 8:33 am | by Mass High Tech: The Journal of New England Technology | Comments

ArQule Inc. has enrolled its first patient in a Phase 1 clinical trial aimed at testing ARQ 736, its small molecule inhibitor of the RAF kinases, ArQule officials announced today in a press release.

Advertisement

KLS Martin's SonicWeld Rx Changing the Face of Craniomaxillofacial Plate Fixation

December 6, 2010 7:34 am | by Bio-Medicine.Org | Comments

TORONTO, Dec. 6, 2010 /- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, US craniomaxillofacial plate and screw market growth will be driven by uptake of new resorbable polymers and novel implantation techniques. KLS Martin's...

TOPICS:

diaDexus to Present at the Canaccord Genuity Healthcare Conference

December 6, 2010 7:34 am | by Bio-Medicine.Org | Comments

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2010 /- diaDexus, Inc. (OTC Bulletin Board: DDXS ), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today said that it plans to...

TOPICS:

CTCs Predict Poor Outcome From Blood Stem Cell Transplantation Therapy for Metastatic Breast Cancer

December 6, 2010 7:34 am | by AACR | Comments

• High-dose chemotherapy and autologous stem cell transplantation is effective therapy. • Therapy may release cancer stem-like cells from bone marrow. • Patients who had low circulating tumor cells did well. SAN ANTONIO - Metastatic breast cancer patients who had circulating tumor cells...

TOPICS:

In the Treatment of COPD, Greater Use in the Primary Care Setting Will Strengthen Spiriva's Position Among Sales Leaders

December 6, 2010 7:33 am | by Bio-Medicine.Org | Comments

BURLINGTON, Mass., Dec. 6, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim/Pfizer's Spiriva will most likely strengthen its position among the sales leaders for the treatment of...

TOPICS:

Compumedics Home Sleep Testing System Selected for Use in US National Institute of Health (NIH)-Sponsored Multi-Ethnic Study of Atherosclerosis (MESA) Sleep Study

December 6, 2010 7:32 am | by Bio-Medicine.Org | Comments

CHARLOTTE, N.C., Dec. 6, 2010 /- Compumedics USA, Inc. (CMP.ASX) today announced its new Somte® PSG portable sleep-testing systems were chosen as part of a major new study to further investigate the link between sleep disorders and cardio-vascular disease in various ethnic and racial...

TOPICS:
Advertisement

JAK inhibitors producing significant response in myelofibrosis patients

December 6, 2010 6:34 am | by EurekAlert | Comments

(Mayo Clinic) Two janus kinase inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology Dec. 4 in Orlando.

TOPICS:

Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program

December 6, 2010 6:32 am | by Bio-Medicine.Org | Comments

EMERYVILLE, Calif., Dec. 6, 2010 /- Wells Fargo Practice Finance, formerly known as Matsco, announced today an agreement to become the preferred provider for optometric practice and equipment financing for American Optometric Association (AOA) members. The affinity relationship through...

TOPICS:

CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti

December 6, 2010 6:32 am | by Bio-Medicine.Org | Comments

SANTA BARBARA, Calif., Dec. 6, 2010 /- Direct Relief International announced today that CSL Behring has donated critically needed medical supplies to assist cholera patients in Haiti. The products will be used at Justinian University Hospital (JUH) in Cap-Haitien. JUH is the main public...

TOPICS:

Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm

December 6, 2010 6:32 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, Dec. 6, 2010 /- Following the annual meeting of its stockholders on Friday, December 3, 2010, Vermillion, Inc. (Nasdaq: VRML ) announced that its stockholders approved the reappointment of Gail S. Page, John F. Hamilton and Dr. William C. Wallen as directors of the Company....

TOPICS:

InVivo exceeds private placement by $2.5M

December 6, 2010 5:33 am | by Mass High Tech: The Journal of New England Technology | Comments

InVivo Therapeutics today said that its previously announced $10.5 million private placement actually brought in $13 milion with additional units being purchased by Spencer Trask Ventures Inc.

Functional Tech Group Sells Wine Yeast to Over 75 US Wineries

December 6, 2010 4:46 am | by The Associated Press | Comments

http://www.functionaltechcorp.com () —Functional Technologies (TSX VENTURE: FEB), a world leader in yeast research and development, today announced sales results of its proprietary hydrogen sulfide (H2S)-preventing wine yeast into the key US market. In its first commercial season, the...

Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting

December 6, 2010 4:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held on December 4-7 in Orlando, FL, the...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading